4,4,4-triphenylbutanal | 16778-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 4,4,4-triphenylbutanal
• 英文别名: 4,4,4-Triphenyl-butyraldehyd
• CAS: 16778-12-4
• 化学式: C₂₂H₂₀O
• 分子量: 300.4
• InChiKey: KSDYVYSEPGULTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  448.9±44.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,4,4-triphenylbutanal 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 50.5h， 生成 2-(benzylamino)-5,5,5-triphenylpentanoic acid
  参考文献：
  名称：

  Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity

  摘要：

  The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.

  DOI：

  10.1021/jm201195m
• 作为产物：
  描述：

  4,4',4''-triphenylbutanoyl chloride 在 lithium aluminium tetrahydride 作用下， 生成 4,4,4-triphenylbutanal
  参考文献：
  名称：

  Lead tetraacetate oxidation of 4,4,4-triphenyl-1-butanol, 3,3,3-triphenyl-1-propanol, and 4,4,4-triphenylbutyric acid

  摘要：

  DOI：

  10.1021/jo01271a034

文献信息

• Yield and selectivity enhancement by trimethylsilyl chloride in the conjugate addition of stabilized organolithiums
  作者：Hong Liu、Theodore Cohen

  DOI：10.1016/0040-4039(95)01919-9

  日期：1995.12

  The yield and selectivity in the conjugate addition of some stabilized organolithiums to α,β-unsaturated carbonyl compounds, especially easily polymerized ones, are increased in the presence of trimethylsilyl chloride, alone or in combination with hexamethylphosphoric triamide. E-silyl enol ethers bearing the versatile phenylthio group are obtained prior to hydrolysis. Some synthetic uses are demonstrated

  在三甲基甲硅烷基氯的存在下，单独或与六甲基磷酸三酰胺结合使用，可以稳定地将某些稳定的有机锂共轭添加到α，β-不饱和羰基化合物中，尤其是易于聚合的化合物中，从而提高收率和选择性。在水解之前，获得带有通用的苯硫基的E-甲硅烷基烯醇醚。证明了一些合成用途。
• JPS59196311A
  申请人：——

  公开号：JPS59196311A

  公开（公告）日：1984-11-07
• Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity
  作者：Fang Wang、James A. D. Good、Oliver Rath、Hung Yi Kristal Kaan、Oliver B. Sutcliffe、Simon P. Mackay、Frank Kozielski

  DOI：10.1021/jm201195m

  日期：2012.2.23

  The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.
• Lead tetraacetate oxidation of 4,4,4-triphenyl-1-butanol, 3,3,3-triphenyl-1-propanol, and 4,4,4-triphenylbutyric acid
  作者：W. H. Starnes

  DOI：10.1021/jo01271a034

  日期：1968.5